One developer of a weight loss medication, clinical-stage biotech Structure Therapeutics ( GPCR 0.16%), was a victim of a ...

Compounding pharmacies aren’t the only makers of off-brand versions of Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound. The situation is causing the FDA regulatory headaches and, more seriously, posing ...

Given the number of comorbidities associated with obesity, the market's growth will impact the entire cardiometabolic disease ...

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide ... ZLDPF), Terns Pharmaceuticals (TERN) and Structure Therapeutics (GPCR).

Hims & Hers Health, Inc. is a dramatically undervalued company if your holding period can be measured in decades. Read more ...

The type 2 diabetes medication, generically known as semaglutide, has received unprecedented ... In the 1990s, Lotte Bjerre Knudsen, a Novo Nordisk researcher who previously studied detergent ...

Political uncertainty in some of the largest European economies has diminished their growth outlook. Read more here.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...